Fahd N. Yunus, MD
Cardiovascular Disease (Cardiology) · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health · Good Samaritan Hospital. That is not proof they admit you there this week.
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Yunus’s office at (408) 739-6000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A143879 · Current
Licensed to practise in California · since 2016 · expires 2027-11-30 · New York Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$373,580
Medicare paid this office $373,580 for 1,329 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 426 | $69,493 | $112 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 207 | $40,282 | $188 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 82 | $39,652 | $466 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 143 | $39,304 | $105 |
| Ultrasound of both sides of head and neck blood flow | 105 | $20,734 | $196 |
See all 43 services
| Return visit (30+ min) | 426 | $69,493 | $112 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 207 | $40,282 | $188 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 82 | $39,652 | $466 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 143 | $39,304 | $105 |
| Ultrasound of both sides of head and neck blood flow | 105 | $20,734 | $196 |
| New patient visit (45+ min) | 126 | $18,385 | $146 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 236 | $14,587 | $61 |
| Long return visit (40+ min) | 55 | $11,606 | $166 |
| Transitional care management services for problem of high complexity | 41 | $11,126 | $271 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 48 | $10,987 | $229 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 90 | $10,764 | $116 |
| Ct scan of blood vessels and grafts of heart with contrast | 64 | $6,431 | $100 |
| New patient visit (60+ min) | 29 | $5,618 | $194 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 19 | $5,415 | $285 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 373 | $5,182 | $13 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $4,815 | $150 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 58 | $3,822 | $64 |
| Ultrasound study of arm and leg arteries | 46 | $3,793 | $82 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 17 | $3,131 | $184 |
| Ultrasound of heart with probe in esophagus, with report | 28 | $3,029 | $95 |
| Short return visit (20+ min) | 33 | $2,846 | $81 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 23 | $2,814 | $122 |
| Telephone medical discussion with physician, 11-20 minutes | 33 | $2,614 | $75 |
| Ultrasound of leg arteries or artery grafts | 11 | $2,401 | $218 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 30 | $1,847 | $22 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 78 | $1,711 | $21 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 30 | $1,677 | $20 |
| Ultrasound of one leg arteries or artery grafts | 12 | $1,675 | $140 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 72 | $1,536 | $10 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 48 | $1,232 | $26 |
| Injection, regadenoson, 0.1 mg | 54 | $1,047 | None |
| Heart rhythm recording of continous external ekg over 8-15 days | 77 | $991 | $12 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 35 | $930 | $27 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 13 | $884 | $68 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, with interpretation and report | 23 | $730 | $32 |
| Ultrasound of heart blood flow, valves and chambers | 13 | $691 | $53 |
| Programming of dual lead pacemaker system | 19 | $666 | $33 |
| Telephone medical discussion with physician, 5-10 minutes | 13 | $646 | $50 |
| 3d radiographic procedure with computerized image postprocessing | 15 | $509 | $34 |
| Ultrasound of heart blood flow, valves and chambers | 29 | $508 | $16 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 27 | $406 | $15 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 12 | $229 | $19 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 27 | $83 | $3 |
Who their Medicare patients are
1,329 Original Medicare patients in 2024. Average age 78 · Under 65 3% · 85 and older 21% · Women 52% · Also on Medicaid 11% · Health risk score 1.33. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 39% · Atrial fibrillation 33% · Diabetes 32% · Chronic kidney disease 28% · Heart failure 24% · Cancer 20% · Depression 16% · COPD 14% · Stroke 14% · Dementia 11%.
The office billed $1,743,560, Medicare allowed $493,356 and paid $373,580; for 4,051 services of 72 kinds; $1,387 of it was for drugs given in the office and $372,193 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,329 | 4,051 | 78 | 1.33 | $1,743,560 | $373,580 |
| 2023 | 882 | 3,209 | 78 | 1.28 | $1,149,028 | $270,378 |
| 2022 | 774 | 3,101 | 78 | 1.25 | $1,164,092 | $311,057 |
| 2021 | 365 | 1,373 | 79 | 1.27 | $521,763 | $151,070 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 33 services
| Return visit (30+ min) | 337 | $58,141 | $110 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 111 | $34,278 | $106 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 166 | $32,362 | $191 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 54 | $25,159 | $466 |
| New patient visit (45+ min) | 111 | $16,647 | $150 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 185 | $11,331 | $58 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 42 | $9,314 | $222 |
| Transitional care management services for problem of high complexity | 27 | $8,175 | $264 |
| Long return visit (40+ min) | 36 | $7,666 | $170 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 58 | $6,846 | $116 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $5,313 | $152 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 79 | $5,129 | $65 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 78 | $4,698 | $30 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 16 | $4,677 | $71 |
| Injection, regadenoson, 0.1 mg | 26 | $4,591 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 343 | $4,521 | $12 |
| Ct scan of blood vessels and grafts of heart with contrast | 43 | $4,431 | $103 |
| New patient visit (60+ min) | 16 | $2,957 | $185 |
| Telephone medical discussion with physician, 11-20 minutes | 33 | $2,704 | $73 |
| Ultrasound of heart with probe in esophagus, with report | 19 | $1,702 | $90 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 72 | $1,660 | $22 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 29 | $1,409 | $24 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 31 | $1,365 | $23 |
| Short return visit (20+ min) | 16 | $1,217 | $76 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 41 | $1,051 | $26 |
| Heart rhythm recording of continous external ekg over 8-15 days | 72 | $938 | $13 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 13 | $845 | $22 |
| Programming of dual lead pacemaker system | 15 | $591 | $35 |
| Telephone medical discussion with physician, 5-10 minutes | 13 | $517 | $40 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 18 | $478 | $27 |
| Ultrasound of heart blood flow, valves and chambers | 22 | $337 | $15 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 12 | $231 | $19 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 19 | $50 | $3 |
2022: 31 services
| Return visit (30+ min) | 335 | $64,306 | $110 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 210 | $40,861 | $188 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 119 | $34,974 | $91 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 63 | $34,252 | $272 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 68 | $33,027 | $486 |
| New patient visit (45+ min) | 92 | $13,618 | $148 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 155 | $9,889 | $60 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 38 | $8,655 | $228 |
| Transitional care management services for problem of high complexity | 26 | $7,399 | $274 |
| Injection, regadenoson, 0.1 mg | 35 | $6,815 | None |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 51 | $6,800 | $121 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $5,368 | $179 |
| Long return visit (40+ min) | 26 | $4,897 | $175 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 324 | $4,397 | $13 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 70 | $4,369 | $62 |
| New patient visit (60+ min) | 24 | $4,028 | $168 |
| Ct scan of blood vessels and grafts of heart with contrast | 33 | $3,193 | $97 |
| Telephone medical discussion with physician, 11-20 minutes | 31 | $2,354 | $74 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 70 | $1,662 | $23 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 33 | $1,546 | $23 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 14 | $1,495 | $25 |
| Short return visit (20+ min) | 16 | $1,485 | $87 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 30 | $1,484 | $25 |
| Ultrasound of heart with probe in esophagus, with report | 15 | $1,473 | $98 |
| Heart rhythm recording of continous external ekg over 8-15 days | 68 | $1,025 | $15 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 38 | $998 | $26 |
| Programming of dual lead pacemaker system | 16 | $600 | $32 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 11 | $597 | $24 |
| Ultrasound of heart blood flow, valves and chambers | 16 | $262 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 11 | $218 | $20 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 14 | $40 | $3 |
2021: 19 services
| Return visit (30+ min) | 220 | $35,028 | $124 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 107 | $23,039 | $215 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 36 | $18,800 | $522 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $14,830 | $95 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 36 | $12,756 | $177 |
| New patient visit (60+ min) | 43 | $8,931 | $208 |
| Injection, regadenoson, 0.1 mg | 23 | $4,388 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,854 | $184 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 14 | $3,537 | $253 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 27 | $3,471 | $124 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 47 | $3,462 | $65 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 177 | $2,654 | $14 |
| New patient visit (45+ min) | 16 | $2,575 | $161 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 36 | $2,252 | $63 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 29 | $730 | $25 |
| Heart rhythm recording of continous external ekg over 8-15 days | 28 | $464 | $17 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 15 | $425 | $28 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 14 | $387 | $28 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 12 | $337 | $28 |
Medicaid work
$451 in 2024
Medicaid paid $451 for 30 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 13 | $410 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 17 | $40 |
| 2024 | 30 | 2 | 13 | $451 |
| 2023 | 89 | 2 | 18 | $537 |
| 2022 | 48 | 1 | 19 | $248 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 75 | $313 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 14 | $224 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 48 | $248 |
Drugs they prescribed that Part D paid
$620,374
Pharmacies billed $620,374 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,710) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
2,286 generic and 424 brand-name prescriptions · $620,374 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 221 | $335,026 | $1,516 |
| Repatha Sureclick | 69 | $77,601 | $1,125 |
| Jardiance | 36 | $56,481 | $1,569 |
| Xarelto | 29 | $44,204 | $1,524 |
| Entresto | 21 | $34,647 | $1,650 |
See all 40 drugs
| Eliquis | 221 | $335,026 | $1,516 |
| Repatha Sureclick | 69 | $77,601 | $1,125 |
| Jardiance | 36 | $56,481 | $1,569 |
| Xarelto | 29 | $44,204 | $1,524 |
| Entresto | 21 | $34,647 | $1,650 |
| Metoprolol | 291 | $4,790 | $16 |
| Flecainide Acetate | 50 | $3,639 | $73 |
| Atorvastatin | 275 | $3,494 | $13 |
| Diltiazem 24hr Er (Cd) | 62 | $2,564 | $41 |
| Midodrine | 14 | $2,480 | $177 |
| Amlodipine Besylate | 204 | $2,249 | $11 |
| Rosuvastatin | 95 | $1,682 | $18 |
| Ezetimibe | 72 | $1,544 | $21 |
| Losartan | 140 | $1,453 | $10 |
| Carvedilol | 99 | $1,311 | $13 |
| Potassium Chloride | 52 | $1,214 | $23 |
| Sotalol Af | 22 | $1,038 | $47 |
| Lisinopril | 68 | $984 | $14 |
| Isosorbide Mononitrate Er | 55 | $958 | $17 |
| Olmesartan Medoxomil | 14 | $904 | $65 |
| Amiodarone | 23 | $847 | $37 |
| Clopidogrel | 44 | $805 | $18 |
| Sotalol | 24 | $667 | $28 |
| Furosemide | 102 | $610 | $6 |
| Simvastatin | 40 | $596 | $15 |
| Verapamil Er | 21 | $588 | $28 |
| Hydralazine | 41 | $581 | $14 |
| Metoprolol | 86 | $545 | $6 |
| Hydrochlorothiazide | 75 | $474 | $6 |
| Valsartan | 20 | $466 | $23 |
| Digoxin | 15 | $435 | $29 |
| Losartan-Hydrochlorothiazide | 26 | $395 | $15 |
| Diltiazem 24hr Er (Xr) | 14 | $393 | $28 |
| Spironolactone | 22 | $281 | $13 |
| Nifedipine Er | 13 | $269 | $21 |
| Atenolol | 13 | $142 | $11 |
| Pravastatin | 14 | $132 | $9 |
| Nitroglycerin | 17 | $125 | $7 |
| Clonidine | 12 | $122 | $10 |
| Ramipril | 18 | $89 | $5 |
Year by year
| 2024 | 2,710 | 402 | 0% (0) | 16% | $620,374 |
| 2023 | 2,154 | 313 | 0% (0) | 12% | $391,907 |
| 2022 | 2,016 | 266 | 0% (0) | 14% | $347,193 |
| 2021 | 591 | 165 | 0% (0) | 13% | $81,296 |
| 2020 | 134 | 34 | 0% (0) | 12% | $10,620 |
| 2019 | 113 | 38 | 0% (0) | 13% | $10,248 |
| 2017 | 14 | None | 0% (0) | 0% | $178 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 36 drugs
| Eliquis | 158 | $238,046 | $1,507 |
| Xarelto | 33 | $45,923 | $1,392 |
| Repatha Sureclick | 24 | $33,754 | $1,406 |
| Jardiance | 11 | $15,580 | $1,416 |
| Metoprolol | 250 | $4,936 | $20 |
| Diltiazem 24hr Er (Cd) | 66 | $3,351 | $51 |
| Flecainide Acetate | 40 | $2,649 | $66 |
| Ezetimibe | 54 | $2,563 | $47 |
| Atorvastatin | 201 | $2,072 | $10 |
| Isosorbide Mononitrate Er | 62 | $1,889 | $30 |
| Amlodipine Besylate | 182 | $1,883 | $10 |
| Potassium Chloride | 51 | $1,829 | $36 |
| Losartan | 116 | $1,593 | $14 |
| Rosuvastatin | 67 | $1,222 | $18 |
| Sotalol | 25 | $971 | $39 |
| Sotalol Af | 15 | $913 | $61 |
| Verapamil Er | 23 | $910 | $40 |
| Carvedilol | 60 | $834 | $14 |
| Furosemide | 86 | $664 | $8 |
| Olmesartan Medoxomil | 13 | $592 | $46 |
| Losartan-Hydrochlorothiazide | 34 | $589 | $17 |
| Clopidogrel | 36 | $576 | $16 |
| Digoxin | 11 | $540 | $49 |
| Hydralazine | 26 | $539 | $21 |
| Lisinopril | 52 | $521 | $10 |
| Pravastatin | 13 | $488 | $38 |
| Nitroglycerin | 25 | $442 | $18 |
| Metoprolol | 63 | $441 | $7 |
| Valsartan | 15 | $415 | $28 |
| Nifedipine Er | 11 | $380 | $35 |
| Simvastatin | 38 | $350 | $9 |
| Clonidine | 15 | $298 | $20 |
| Atenolol | 22 | $263 | $12 |
| Spironolactone | 15 | $181 | $12 |
| Hydrochlorothiazide | 45 | $172 | $4 |
| Ramipril | 15 | $122 | $8 |
2022: 35 drugs
| Eliquis | 171 | $221,349 | $1,294 |
| Xarelto | 34 | $50,124 | $1,474 |
| Repatha Sureclick | 17 | $19,964 | $1,174 |
| Metoprolol | 240 | $4,631 | $19 |
| Flecainide Acetate | 37 | $3,224 | $87 |
| Atorvastatin | 209 | $2,374 | $11 |
| Diltiazem 24hr Er (Cd) | 65 | $2,345 | $36 |
| Ezetimibe | 44 | $2,087 | $47 |
| Potassium Chloride | 50 | $1,509 | $30 |
| Amlodipine Besylate | 160 | $1,395 | $9 |
| Rosuvastatin | 55 | $1,358 | $25 |
| Sotalol Af | 26 | $1,237 | $48 |
| Isosorbide Mononitrate Er | 42 | $1,231 | $29 |
| Sotalol | 27 | $1,105 | $41 |
| Losartan | 102 | $999 | $10 |
| Carvedilol | 39 | $755 | $19 |
| Losartan-Hydrochlorothiazide | 26 | $720 | $28 |
| Hydralazine | 19 | $711 | $37 |
| Diltiazem 24hr Er | 12 | $642 | $53 |
| Lisinopril | 67 | $636 | $9 |
| Amiodarone | 16 | $480 | $30 |
| Clopidogrel | 27 | $479 | $18 |
| Nitroglycerin | 21 | $475 | $23 |
| Furosemide | 81 | $436 | $5 |
| Metoprolol | 49 | $429 | $9 |
| Olmesartan Medoxomil | 11 | $323 | $29 |
| Simvastatin | 41 | $309 | $8 |
| Verapamil Er | 12 | $290 | $24 |
| Spironolactone | 18 | $286 | $16 |
| Pravastatin | 14 | $276 | $20 |
| Triamterene-Hydrochlorothiazid | 11 | $214 | $19 |
| Warfarin | 13 | $199 | $15 |
| Hydrochlorothiazide | 46 | $196 | $4 |
| Atenolol | 24 | $192 | $8 |
| Clonidine | 16 | $124 | $8 |
2021: 14 drugs
| Eliquis | 39 | $50,486 | $1,295 |
| Metoprolol | 48 | $1,156 | $24 |
| Atorvastatin | 61 | $1,057 | $17 |
| Diltiazem 24hr Er (Cd) | 13 | $782 | $60 |
| Carvedilol | 38 | $585 | $15 |
| Amlodipine Besylate | 43 | $495 | $12 |
| Lisinopril | 40 | $451 | $11 |
| Isosorbide Mononitrate Er | 12 | $358 | $30 |
| Ranolazine Er | 14 | $341 | $24 |
| Spironolactone | 16 | $250 | $16 |
| Furosemide | 34 | $215 | $6 |
| Losartan | 16 | $192 | $12 |
| Metoprolol | 16 | $151 | $9 |
| Simvastatin | 12 | $82 | $7 |
2020: 4 drugs
| Ranolazine Er | 13 | $992 | $76 |
| Metoprolol | 13 | $244 | $19 |
| Atorvastatin | 14 | $200 | $14 |
| Carvedilol | 19 | $116 | $6 |
2019: 2 drugs
| Atorvastatin | 13 | $210 | $16 |
| Furosemide | 15 | $125 | $8 |
2017: 1 drug
| Atorvastatin | 12 | $66 | $6 |
Money from drug and device companies
$68 in 2021
| 2021 | 1 | 2 | None | $68 |
| 2020 | 2 | 2 | None | $53 |
| 2019 | 2 | 4 | None | $94 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Lantheus Medical Imaging | Definity | $68 | 2 payments
|
See all 2 published payments
| Lantheus Medical Imaging | Meals · 2021-05-03 | Definity | $34 |
| Lantheus Medical Imaging | Meals · 2021-03-01 | Definity | $34 |
See earlier years (2020, 2019)
2020: $53
| Lantheus Medical Imaging | Definity | $31 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $22 | 1 payment
|
2019: $94
| Amgen | Corlanor | $74 | 3 payments
|
| Pfizer | Eliquis | $20 | 1 payment
|
Professional record
- NPI
- 1922493782
- Licence
- CA A143879California A143879: Current · expires 2027-11-30
- Trained
- New York Medical College, 2015
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X); Student in a training program (390200000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2015-03-30
- NPI last updated
- 2021-07-28
- NPI record certified
- 2021-07-28
This is when the NPI record was last certified, not a medical board exam.